Is IX Biopharma Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, IX Biopharma Ltd (42C.SI) is currently classified as HALAL as of October 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is IX Biopharma Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes IX Biopharma Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of IX Biopharma Ltd?

Muslim investors may consider investing in IX Biopharma Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is IX Biopharma Ltd classified as HALAL?

Musaffa determines the Shariah status of IX Biopharma Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for IX Biopharma Ltd updated?

The Shariah compliance status of IX Biopharma Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like IX Biopharma Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of IX Biopharma Ltd?

You can check the latest Shariah compliance status of IX Biopharma Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

IX Biopharma Ltd 42C.SI

SGD0.20 SGD0.01 (4.76%) 1D

Last Updated: Apr 09, 12:00 AM·SGX

42C.SI Shariah Compliance

Screening Methodology: AAOIFI

UNLOCK FOR FREE

Last Updated: October 07, 2025

Report Source: 2025 Annual Report

Analyst's Ratings for IX Biopharma Ltd (42C.SI)

Based on 5 analysts giving stock ratings to IX Biopharma Ltd in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

IX Biopharma Ltd. Stock Analysis 42C.SI

Singapore Health Care Micro Cap Report: 2025 Annual

iX Biopharma Ltd. engages in the provision of development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development, manufacturing and commercialization of therapies for the treatment of acute and breakthrough pain and other health conditions. Its drug delivery platform technologies are WaferiX, WaferlogiX, and NADiX, which deliver small molecule and biologics. The Company’s segments include Specialty Pharmaceutical and Nutraceutical segments. The Specialty Pharmaceutical segment’s primary business activities are the development and manufacturing of products, and sales of pharmaceutical and medicinal cannabis products. The Nutraceutical segment’s primary business activities are the sale of nutraceutical products.

Key Statistics of IX Biopharma Ltd (42C.SI)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

SGD0.20SGD0.21

Today's Open

SGD0.21

Volume

6.43M

P/E Ratio (TTM)

52 Week Range

SGD0.02SGD0.25

Market Cap

176.52M

Avg. Volume

10.71M

Dividend Yield

Financial Metrics & Statements of IX Biopharma Ltd (42C.SI)

Community-Curated Collections with IX Biopharma Ltd (42C.SI) ( With 42C.SI )

View All

Community-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.

Halal Stocks in Singapore’s Health Care Sector

By Investment Alchemist

2 Followers

+7 more

FAQ's for IX Biopharma Ltd (42C.SI)

According to Musaffa’s Shariah screening methodology, IX Biopharma Ltd (42C.SI) is currently classified as HALAL as of October 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.